SIBN icon

SI-BONE Inc

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 66.7%
Negative

Positive
Zacks Investment Research
16 days ago
How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%
The consensus price target hints at a 65.3% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%
Neutral
Seeking Alpha
19 days ago
SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SI-BONE, Inc. (SIBN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral
Seeking Alpha
19 days ago
SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript
SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript
SI-BONE, Inc. (SIBN) Q1 2026 Earnings Call Transcript
Positive
MarketBeat
20 days ago
SiBone Q1 Earnings Call Highlights
SiBone NASDAQ: SIBN raised its full-year 2026 outlook after reporting double-digit revenue growth in the first quarter, with management pointing to new product launches, expanding physician adoption, international momentum and a proposed Medicare reimbursement change as key drivers for the year ahead.
SiBone Q1 Earnings Call Highlights
Negative
Zacks Investment Research
20 days ago
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.15 per share a year ago.
Si-Bone (SIBN) Reports Q1 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
20 days ago
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA Delivered ~11% worldwide revenue growth, record physician engagement and ~440% improvement in adjusted EBITDA
SI-BONE, Inc. Reports Financial Results for the First Quarter 2026 and Raises 2026 Guidance
Neutral
Seeking Alpha
25 days ago
First Eagle Small Cap Opportunity Fund Q1 2026 Portfolio Review
Leading contributors in the First Eagle Small Cap Opportunity Fund this quarter included Ultra Clean Holdings, Oil States International, Lincoln Educational Services, Advanced Energy and FormFactor. Oil States International shares rallied on very strong bookings during the quarter and improved operator-powered solutions and services inside the wellbore. The leading detractors in the quarter were Vital Farms, Alphatec Holdings, Beta Bionics, SI-BONE. and Herc Holdings.
First Eagle Small Cap Opportunity Fund Q1 2026 Portfolio Review
Neutral
GlobeNewsWire
1 month ago
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
SANTA CLARA, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced that the company will be participating in the upcoming 2026 BofA Securities Healthcare Conference in Las Vegas, NV. Management will be hosting a fireside chat on Tuesday, May 12, 2026, at 8:00 a.m. Pacific Time/11:00 a.m. Eastern Time.
SI-BONE To Present at BofA Securities 2026 Healthcare Conference on May 12, 2026
Neutral
GlobeNewsWire
1 month ago
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
SANTA CLARA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), the global leader in developing procedural solutions to address clinical challenges associated with compromised bone, today announced it will report financial results for the first quarter of 2026 after market close on Monday, May 11, 2026. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time
SI-BONE To Report First-Quarter 2026 Financial Results on May 11, 2026
Negative
Zacks Investment Research
3 months ago
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
Si-Bone (SIBN) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.11 per share a year ago.
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates